Clear All
793 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 0.625 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Vandetanib Caprelsa 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
NA Cysteamine Bitartrate Procysbi 25mg, 75mg, 300mg Chemotherapy Cystine-Depleting Agent Yes 2013 In Use
NA Erlotinib Tarceva 150 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Dasatinib Sprycel 70 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Nintedanib Ofev 150 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
NA Lenalidomide Revlimid 5 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2005 In Use
NA Larotrectinib Vitrakvi 25mg, 100mg 20mg/ml Chemotherapy Tyrosine Kinase Inhibitor TRK Yes 2018 In Use
NA Panobinostat Farydak 10 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERɑ Yes 2023 In Use
NA Sorafenib Nexavar 200 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET, CRAF, BRAF Yes 2005 In Use
NA Cabozantinib Cabometyx 60 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
NA Umbralisib Ukoniq 260.2mg Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Yes 2021 In Use
NA ixazomib Ninlaro 3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA Aprepitant Emend 40 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA olaparib Lynparza 50 mg Chemotherapy Enzyme Inhibitor PARP Yes 2014 In Use
NA Rucaparib Rubraca 200 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.